Skip to content

Supine MRI-guided navigation for tumor localization in breast cancer patients: a feasibility study.

Supine MRI-guided navigation for tumor localization in breast cancer patients: a feasibility study. - MRI-guided navigation for tumor localization in breast cancer patients.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON43198
Enrollment
20
Registered
2016-10-12
Start date
2017-03-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive breast cancer

Interventions

On the day of the marker implantation, a supine contrast-enhanced (CE) MRI is acquired. After the implantation procedure, a CT without contrast agent is acquired.
Breast cancer
Electromagnetism

Sponsors

Antoni van Leeuwenhoek Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: • Patients with an invasive breast carcinoma, visible on prone CE-MRI. • Patients who are scheduled for single-seed RSL. • A signed informed consent. • Patients >= 18 years old.

Exclusion criteria

Exclusion criteria: • Contraindication for MRI in supine position or CT. • Contraindication for gadolinium contrast administration.

Design outcomes

Primary

MeasureTime frame
The primary outcome of the study is the accuracy of the supine MRI-guided navigated tumor marker implantation. The accuracy is defined as the difference between planned marker location on supine MRI and actual marker location as seen on CT which is acquired after the implantation procedure.

Secondary

MeasureTime frame
The secondary outcome of the study is the variability in target volume delineations on pre-operative supine CT with that of registered supine CT-MR scans. The variability is defined as the difference in standard deviation on the surface distance maps between the delineations made on CT only compared to that of registered MR-CT.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)